Loading…
French animal-health company making veterinary medicines and health products for pets and farm animals.
French animal-health company making veterinary medicines and health products for pets and farm animals.
Sells animal medicines to veterinarians directly and through distributors, so growth follows vets' prescribing habits and product registrations in each country. The founding Vetoquinol family still controls the group.
In one line: A smaller French Zoetis/Elanco.
Moat: narrow (regulatory licence, brand, distribution). Established veterinary product registrations and distribution in Europe, but small next to global animal-health leaders.
Headquarters: Lure, France · Founded: 1933 · Employees: 2,501
Size Vetoquinol (VETO.PA) is a France Health Care company (Pharmaceuticals: Major) with a market value of $1.17B, the 129th largest of 206 France companies the cockpit tracks. Shares closed at €88.40 on 6 Nov 2026.
Performance Over six months the shares gained 22.3%, against -10.5% for the median peer and -0.4% for the France market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue fell 0.9% over the last twelve months (peer median -0.2%); the operating margin is 14.8% (peer median 6.4%).
Valuation It trades at 15.8× forward earnings against a peer median of 19.6× (6th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.1 points above its cost of capital (7.9% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €527M | €526M | €539M | €529M | €540M |
| Revenue growth | — | -3% | +2% | -2% | — |
| Gross profit | €84.6M | €160M | €159M | €158M | €172M |
| EBITDA | €110M | €105M | €102M | €97.3M | €111M |
| Net income | €62.8M | €57.4M | €58.7M | €55.6M | €48.0M |
| Free cash flow | €87.1M | €59.0M | €75.9M | €76.2M | €45.4M |
| Capital expenditure | €18.6M | €20.7M | €17.7M | €19.0M | €22.5M |
| Total debt | n/a | €15.3M | €21.1M | €17.6M | €17.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Vetoquinol VETO.PA | $1.17B | +22% | -1% | 15% | 15.8× | -3.0% |
| Zoetis ZTS | $32.8B | -4% | +1% | 38% | 12.8× | -4.3% |
| Elanco Animal Health ELAN | $12.9B | +9% | +12% | 7% | 21.8× | 34.8% |
| Virbac VIRP.PA | $3.38B | +5% | +4% | 15% | 17.2× | 6.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VETO.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +17.4% | -4.1% | 2nd highest of 21 |
| 6-month return | +22.3% | -10.5% | 4th highest of 21 |
| Distance from 52-week high | -3.4% | -31.2% | highest of 21 |
| Revenue growth (TTM) | -0.9% | -0.2% | 10th highest of 19 |
| Operating margin | 14.8% | 6.4% | 8th highest of 20 |
| Forward P/E | 15.8× | 19.6× | 6th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | -3.0% | 3.9% | 2nd least demanding of 13 |
| Growth delivered (Del g) | +4.2% | +8.9% | 5th lowest of 13 |
| Hurdle (Req g minus delivered) | -7.2 pp | -0.4 pp | 4th least demanding of 13 |
| ROIC minus cost of capital | +7.1 pp | -0.2 pp | 3rd highest of 19 |
| EV / EBITDA | 7.5× | 12.1× | cheapest of 4 |
| Net debt / EBITDA | -2.0× | -0.4× | least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 15.8× | -3.0% | +4.2% |
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 432.6× | n/a | n/a |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 85.2× | 16.2% | +19.4% |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | n/a | 1.4% | -4.2% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 19.6× | 5.8% | +11.3% |
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 5.0× | 8.3% | +5.8% |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | n/a | 10.4% | -60.6% |
| Jiuzhitang 000989.SZ | China | $1.19B | -13% | +46% | 19% | 22.7× | -3.7% | -9.0% |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | n/a | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 19.6× | 4.5% | -1.2% |
| Amphastar Pharmaceuticals AMPH | United States | $1.21B | +50% | +1% | 16% | 8.9× | 3.3% | +15.5% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 15.4× | 1.5% | +18.7% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 12.8× | 1.1% | +22.8% |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 26.9× | n/a | n/a |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 7.7× | n/a | n/a |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 27.9× | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | n/a | 3.3% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% | +13.8% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | n/a | n/a | n/a |